Alpha-9 Oncology

Executive Summary

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company founded in 2020, headquartered in Cambridge, MA, with operations in Vancouver, Canada. The company is developing a pipeline of highly selective and potent targeted radiotherapies for cancer through a proprietary iterative engineering platform that optimizes all components of the radiopharmaceutical molecule—binder, linker, chelator, and radioisotope—to deliver precise radiation to tumor cells. By focusing on the entire molecular design, Alpha-9 aims to improve therapeutic index and address limitations of traditional radiotherapies. The company is currently in Phase 1 clinical development, leveraging its platform to create best-in-class candidates for solid tumors. Alpha-9's lead program is advancing through dose escalation in a Phase 1 trial, with early safety and efficacy data expected in the coming quarters. The company's differentiated approach and experienced management team position it well within the competitive radiopharmaceutical landscape. While still early-stage, Alpha-9 has the potential to become a leader in targeted radionuclide therapy if its platform delivers on its promise. Key upcoming catalysts include initial clinical data readouts, expansion of the pipeline through IND filings, and potential strategic partnerships to support broader development and manufacturing capabilities.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 dose-escalation data for lead radiopharmaceutical candidate60% success
• TBDIND submission for next-generation radiopharmaceutical candidate50% success
• TBDResearch collaboration or licensing deal with a larger pharma company30% success